Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1045 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1045.

November 28, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Regeneron Pharmaceuticals with a price target of $1045, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst like Robyn Karnauskas from Truist Securities could lead to increased investor confidence in Regeneron Pharmaceuticals. This endorsement is likely to have a positive impact on the stock price in the short term as it suggests the analyst's belief in the company's potential for growth and value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100